Muenster

• Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT) Recruiting
  2025-521051-23-00 4 2025-08-06 metastatic castration-resistant prostate cancer
• A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima … Recruiting
  2024-518893-15-00 5 2025-07-29 Chronic lymphotic leukemia and Small Lymphocytic lymphoma
• Phase 3 Study of Ravulizumab versus Placebo in Adult Participants at High Risk of DGF after Kidney Transplantation (AWAKE) Recruiting
  2024-517568-48-00 5 2025-07-21 Delayed Graft Function after Kidney Transplantation
• A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an … Recruiting
  2024-516162-11-00 5 2025-07-14 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
• A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s … Recruiting
  2024-513682-40-01 5 2025-07-04 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
• A clinical study of patritumab deruxtecan (HER3-DXd) in children with cancer (MK-9999-01C) Recruiting
  2024-518771-66-00 9 2025-07-01 Hepatoblastoma, Rhabdomyosarcoma
• Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenab … Recruiting
  2024-515646-16-00 4 2025-06-24 Recurrent, persistent, metastatic or locally advanced vulvar cancer
• Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation (alloSCT) In Patients with Acute Myeloid Leu … Recruiting
  2023-509055-14-00 4 2025-06-17 myelodysplastic neoplasia (MDS)
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient … Recruiting
  2023-510026-32-00 5 2025-06-11 Generalized Myasthenia Gravis
• A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge … Recruiting
  2023-509547-27-00 5 2025-05-22 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16 Diffuse Large B-Cell Lymphoma (DLBCL)
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 Non-Small Cell Lung Cancer
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto … Recruiting
  2023-504180-16-00 5 2025-04-07 Advanced Breast Cancer
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi … Recruiting
  2023-508076-11-00 5 2025-04-01 Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
• Reduction of occurence of Acute Kidney Injury through administration of angiotensin II versus Noradrenaline Recruiting
  2024-517771-21-00 11 2025-03-31 Acute kidney injury
• A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields), together with temozolo … Recruiting
  2024-513550-30-00 5 2025-03-28 Newly diagnosed Glioblastoma
• CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting
  2024-516248-24-00 5 2025-03-28 Hereditary Angioedema
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia Recruiting
  2022-500574-34-00 4 2025-03-21 Waldenström’s Macroglobulinemia
• A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease Recruiting
  2024-515732-68-00 1 2025-03-07 Huntington’s disease
• Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting
  2022-500747-21-00 4 2025-02-27 Geographic Atrophy
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an

Showing 169–192 of 608 trials